Alisertib
| Title | Journal |
|---|---|
| A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies. | Oncogene 20150601 |
| Discovery of imidazo[1,2-b]pyridazine derivatives: selective and orally available Mps1 (TTK) kinase inhibitors exhibiting remarkable antiproliferative activity. | Journal of medicinal chemistry 20150226 |
| Identification of potent Yes1 kinase inhibitors using a library screening approach. | Bioorganic & medicinal chemistry letters 20130801 |
| Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism. | International journal of cancer 20121201 |
| Development of o-chlorophenyl substituted pyrimidines as exceptionally potent aurora kinase inhibitors. | Journal of medicinal chemistry 20120913 |
| Dual targeting of mTOR and aurora-A kinase for the treatment of uterine Leiomyosarcoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120901 |
| Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL. | Cell 20120803 |
| Development of treatment strategies for advanced neuroblastoma. | International journal of clinical oncology 20120601 |
| Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120415 |
| Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays. | Clinical cancer research : an official journal of the American Association for Cancer Research 20111215 |
| Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. | Cancer chemotherapy and pharmacology 20111101 |
| The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib. | Journal of cellular and molecular medicine 20111001 |
| Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma. | Biochemical pharmacology 20110401 |
| Validation of a flow cytometry based G(2)M delay cell cycle assay for use in evaluating the pharmacodynamic response to Aurora A inhibition. | Journal of immunological methods 20110105 |
| Aurora-A inactivation causes mitotic spindle pole fragmentation by unbalancing microtubule-generated forces. | Molecular cancer 20110101 |
| A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. | Blood 20100624 |
| Drug-resistant aurora A mutants for cellular target validation of the small molecule kinase inhibitors MLN8054 and MLN8237. | ACS chemical biology 20100618 |
| Discovery and development of aurora kinase inhibitors as anticancer agents. | Journal of medicinal chemistry 20090514 |